Eli Lilly), which the FDA suddenly removed from the drug shortage list, resulting in a 5,6 The FDAs removal of tirzepatide from the shortage list without the due process of proper federal notice, at a time when they acknowledge that shortages still exist, is the definition of arbitrary and capricious, said Lee H Rosebush, chairman of OFA, in the news release
Liraglutide (Saxenda/Victoza), which is a daily injection rather than weekly, also uses these same sites but requires more frequent rotation due to daily use
The GTP-bound alpha subunit can move away and activate downstream pathways, and the beta and gamma subunits can also dissociate and trigger complementary pathways
For most users, this effect is manageable